The short version
- Why people research itSignificant fat loss via triple GLP-1/GIP/glucagon agonism.
- What the evidence isPhase 3 has read out: TRIUMPH-4 (11 Dec 2025), TRIUMPH-1 (21 May 2026), and TRIUMPH-2 and TRIUMPH-3 (23 Jul 2026).
- What to watchBelly pain that bores through to the back.
How Retatrutide works
Triple GIP/GLP-1/glucagon receptor agonist — appetite suppression and insulin sensitivity plus glucagon-driven energy expenditure.
Retatrutide is one molecule that has to satisfy three different receptors, and two of them pull in opposite directions. It is a single-chain peptide agonist at the GIP, GLP-1 and glucagon receptors Jastreboff 2023.
Why anyone would add a glucagon agonist on purpose. The glucagon receptor is a class B GPCR concentrated in hepatocytes. Beyond glycogenolysis and gluconeogenesis it drives hepatic fatty acid oxidation and raises resting energy expenditure.
- Injectable
On the goal map: Hepatic fat & fatty liver (Metabolic health & insulin sensitivity)
Research on Retatrutide5 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: Phase 3 human (TRIUMPH-1 to -4 reported; phase 2: 24.2% at 48 weeks).
Human clinical evidence
Phase 2 produced the largest weight loss recorded for any drug in a randomized trial. Phase 3 has read out: TRIUMPH-4 (11 Dec 2025), TRIUMPH-1 (21 May 2026), and TRIUMPH-2 and TRIUMPH-3 (23 Jul 2026).
Lilly plans to file with the FDA in Q1 2027. It isn't approved anywhere.
Correlative data
Widely used ahead of approval through research channels. Reported experience tracks the trial — very strong appetite suppression, and a noticeably higher rate of the heart-rate increase seen in the published data.
How the mechanism reads
A triple agonist: GLP-1, GIP and glucagon. The glucagon arm is the novel part and the reason for the effect size — glucagon receptor agonism raises energy expenditure rather than only reducing intake, so this attacks both sides of the balance where the dual and single agonists attack one.
MechanisticThe same glucagon activity predicts the two things to watch: raised heart rate, and effects on hepatic glucose output that make it less predictable in someone with unstable glycemic control.
Mechanistic
Sources
- Pasqualotto E, et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers. Metabolism Open 2024 · PMID 39318607
Retatrutide safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Personal or family history of medullary thyroid cancer or MEN2: the GLP-1 arm carries the class C-cell signal.
- Pancreatitis history or gallbladder disease: three-receptor appetite suppression speeds weight loss that provokes gallstones.
- Type 1 diabetes or insulin or sulfonylurea use: three insulin-sensitizing arms raise hypoglycemia risk.
- Resting tachycardia or an arrhythmia: the glucagon arm raises heart rate.
- Pregnancy or conception plans: large energy deficits and untested triple agonism do not fit gestation.
What’s expected
- Large appetite drop, through GIP and GLP-1 signaling plus glucagon-driven energy burn.
- Nausea early, easing over weeks.
- Faster resting pulse.
- Some lean mass lost alongside fat, so protein and training matter.
Watch for
- Belly pain that bores through to the back.
- Right-sided pain with fever or yellow eyes while using Retatrutide.
- Heart racing or pounding at rest.
- Dizziness and very little urine after vomiting.
Labs that tell you it’s working
- HbA1c (Hemoglobin A1c)
- Lipase
- Lipid Panel
- Cystatin C with eGFR
Retatrutide is a triple GIP, GLP-1 and glucagon agonist; newer than semaglutide, so fewer outcome trials reflects calendar, not failure. PMID 37366315 PMID 38858523
Bloodwork to runHow you would know it is working: 9 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
The “On a GLP-1 (Semaglutide / Tirzepatide)” panel, explained
Retatrutide FAQ4 common questions
- Is Retatrutide approved for human use?
- No. Retatrutide is a research compound.
- What is Retatrutide researched for?
- Significant fat loss via triple GLP-1/GIP/glucagon agonism.
- Which labs show whether it's doing anything?
- HbA1c; Lipase; Lipid Panel; Cystatin C with eGFR: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Retatrutide: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.





